REFERENCES
1. Narciso, H., Ruelan, J. “Leishmaniasis.” May 2007. http://www.stanford.edu/class/humbio103/ParaSites2006/Leishmaniasis/Index.htm
2. John, D.T. and Petri, W. A. Markell and Voge’s Medical Parasitology, Ninth Edition. Missouri: Saunders Elsevier, 2006.
3. Sher, Alan. Immunobiology Section, Laboratory of Parasitic Diseases, NIAID, NIH. Personal Interview. 22 May 2007.
4. S. Zambrano-Villa S, Rosales-Borjas D., Carrero JC, Ortiz-Ortiz L. "How Protozoa evade the immune response." Trends Parasitol. 2002 Jun; 18(6):272-8.
5. K.J. Moore and G. Matlashewski , Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J. Immunol. 152 (1994), pp. 2930–2937.
6. Goldman, A.S. et. al. “Immunology Overview.” The University of Texas Medical Branch at Galveston. 24 May 2007. http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mmed.chapter.137
7. Lodoen, Melissa. Department of Microbiology and Immunology, Stanford University. Personal Interview. 21 May 2007.
8. Roche, J. P. “Leishmaniasis.” 2002. Boston College. 21 May 2007. http://www.bc.edu/schools/cas/biology/research/infect/leishmaniasis.
9. G. Forget, D. J. Gregory, M. Olivier. “Subversion Mechanisms by Which Leishmania Parasites Can Escape the Host Immune Response: a Signaling Point of View”. Clin Microbiol Rev. 2005 April; 18(2): 293–305.
10.”How Complement Works.” 1999. Brown University. 20 May 2007. http://www.brown.edu/Courses/Bio_160/Projects1999/ies/how.html#Overview.
11. D. Sacks, A. Sher,. “Evasion of Innate Immunity by Parasitic Protozoa.” Nature Immunology. 2002; (3): 1041-1047.
12. Purnima Bandyopadhyay, et. al. Metacyclogenesis of Leishmania spp: Species-Specific In vitro Transformation, Complement Resistance, and Cell Surface Carbohydrate and Protein Profiles. The Journal of Parasitology, 77:3. (1991), pp. 411-416.
13. Handman, Emanuela. “The Leishmania Laboratory.” 2006. The Walter and Eliza Hall Institute of Medical Research. 22 May 2007.
http://www.wehi.edu.au/facweb/indexresearch.php?id=12#section07
14. M. Desjardins and A. Descoteaux , Inhibition of phagolysosomal biogenesis by the Leishmania lipophosphoglycan. J. Exp. Med. 185 (1997), pp. 2061–2068.
15. K.J. Moore and G. Matlashewski , Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J. Immunol. 152 (1994), pp. 2930–2937.
16. A.L. Sorensen et al., Leishmania major surface protease gp63 interferes with the function of human monocytes and neutrophils in vitro. Acta Pathol. Microbiol. Immunol. Scand. 102 (1994), pp. 265–271.
17. N.E. Reiner et al., Parasite accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J. Immunol. 138 (1987), pp. 1926–1932.
18. R.M. Locksley et al., Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science 261 (1993), pp. 1448–1451.
19. McKerrow, James. The McKerrow Lab, University of California San Francisco. Personal Interview. 16 May 2007.
20. Smith, Scott. “Leishmania.” Human Biology 153. Stanford University, 2007.
21. E. Handman. Leishmaniasis: Current Status of Vaccine Development. Clin Microbiol Rev. 14:2 (2001), pp. 229-243.
22. Reilly, Pat. “OneWorld Health’s First Approved Drug Added to WHO Essential Medicines List.” 2007. Institute for OneWorld Health. 23 May 2007. http://www.oneworldhealth.org/media/details.php?prID=173.
23. Dunn, Joe Dan. Microbiology and Immunology, Stanford University. Personal Interview. 16 May 2007.
24. “Fungizone.” 2004. Bristol-Myers Squibb. 23 May 2007. http://www.bmsfinland.com/default.aspx?SelSidID=12823